Trust Co. of Vermont Has $18.90 Million Position in Thermo Fisher Scientific Inc. $TMO

Trust Co. of Vermont increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.3% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 46,616 shares of the medical research company’s stock after buying an additional 126 shares during the quarter. Trust Co. of Vermont’s holdings in Thermo Fisher Scientific were worth $18,901,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Brighton Jones LLC lifted its stake in Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after acquiring an additional 988 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares during the last quarter. NBC Securities Inc. lifted its stake in Thermo Fisher Scientific by 125,200.0% in the first quarter. NBC Securities Inc. now owns 2,506 shares of the medical research company’s stock valued at $1,246,000 after acquiring an additional 2,504 shares during the last quarter. Harbor Investment Advisory LLC lifted its stake in Thermo Fisher Scientific by 30.5% in the first quarter. Harbor Investment Advisory LLC now owns 389 shares of the medical research company’s stock valued at $194,000 after acquiring an additional 91 shares during the last quarter. Finally, Merit Financial Group LLC lifted its stake in Thermo Fisher Scientific by 19.2% in the first quarter. Merit Financial Group LLC now owns 11,746 shares of the medical research company’s stock valued at $5,845,000 after acquiring an additional 1,895 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $484.70 on Wednesday. The stock has a market cap of $183.03 billion, a P/E ratio of 28.03, a PEG ratio of 2.51 and a beta of 0.75. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $620.00. The company has a fifty day moving average price of $478.98 and a 200 day moving average price of $446.98. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock valued at $14,182,963 in the last 90 days. 0.33% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, September 7th. Scotiabank upgraded shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price objective for the company in a research note on Friday, July 11th. Raymond James Financial restated an “outperform” rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Barclays upgraded shares of Thermo Fisher Scientific from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $490.00 to $550.00 in a research note on Thursday, September 11th. Finally, UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research note on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $583.53.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.